Silexion Therapeutics (NASDAQ:SLXN) Stock Moved Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Silexion Therapeutics (NASDAQ:SLXN) to a hold rating in a report issued on Saturday,Wall Street Zen reports.

SLXN has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Silexion Therapeutics Price Performance

Shares of SLXN stock traded down $0.68 on Friday, hitting $1.98. The company’s stock had a trading volume of 103,027 shares, compared to its average volume of 58,917. Silexion Therapeutics has a fifty-two week low of $1.82 and a fifty-two week high of $777.12. The firm’s fifty day moving average price is $5.70 and its 200-day moving average price is $140.28. The stock has a market capitalization of $455,400.00, a price-to-earnings ratio of -0.05 and a beta of -0.30.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Thursday, November 12th. The company reported ($13.70) earnings per share for the quarter, beating the consensus estimate of ($218.40) by $204.70. Analysts predict that Silexion Therapeutics will post -112.71 EPS for the current fiscal year.

About Silexion Therapeutics

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.